S&P 500Health Care· USA

GILD

Status-Quo-Player

Gilead Sciences

$139.03

+0.00%

Open $137.99·Prev $139.03

as of 13 Apr

STATUS-QUO-PLAYER

Power Core

The moat is the compounding clinical evidence base across HIV treatment and prevention, which creates switching costs that operate at the level of medical practice rather than individual prescriptions.

Published1 Apr 2026

UniverseS&P 500

SectorHealth Care

↑

Direction of Movement

Lenacapavir Anchors an Upward Trajectory

ROC 200

+26.1%

Financials